Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanologica ABOSTO:NICA -1.24%46 Debt-to-Equity is 0.34 as of Jun. 2026, which is 100% above its 10-year median of 0.17. GuruFocus rates OSTO:NICA with a GF Score™ of 46/100 and a GF Value™ of kr2.94 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 966 Biotechnology companies, Nanologica AB ranks worse than 67.08% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nanologica AB's Debt-to-Equity or its related term are showing as below:
OSTO:NICA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.87 Med: 0.17 Max: 10.25
Current: 0.34
During the past 12 years, the highest Debt-to-Equity Ratio of Nanologica AB was 10.25. The lowest was -5.87. And the median was 0.17.
OSTO:NICA's Debt-to-Equity is ranked worse than 67.08% of 966
companies
in the Biotechnology industry
Industry Median: 0.15
vs OSTO:NICA: 0.34
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nanologica AB Debt-to-Equity Related Terms
Nanologica AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nanologica AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Nanologica AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nanologica AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB (OSTO:NICA) has a Debt-to-Equity of 0.34 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nanologica AB and its competitors. This is 100% above median its historical median of 0.17. According to the industry distribution chart, Nanologica AB ranks #648 out of 966 companies in the Biotechnology industry, placing it in the top 67.1%.
Is Nanologica AB's Debt-to-Equity too high?
Nanologica AB's current Debt-to-Equity of 0.34 is 100% above median its 10-year median of 0.17. The Biotechnology industry median Debt-to-Equity is 0.15. Nanologica AB's value of 0.34 is 126.7% above this industry median. Based on the distribution chart, Nanologica AB ranks #648 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanologica AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #648 out of 966 companies for Debt-to-Equity. This places Nanologica AB in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Nanologica AB's value of 0.34 is 126.7% above this benchmark. While the company's 10-year median is 0.17 vs. the industry median of 0.15, Nanologica AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanologica AB's current Debt-to-Equity of 0.34 is 126.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nanologica AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanologica AB's current Debt-to-Equity is 0.34, which is 100% above median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.94, compared to a current price of kr0.32 — trading 89.2% below its estimated fair value. The current Debt-to-Equity is 0.34, which is 100% above median its 10-year median of 0.17 and 126.7% above the Biotechnology industry median of 0.15. Nanologica AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Debt-to-Equity is 0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.32 is trading 89.2% below its estimated GF Value™ of kr2.94.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
Debt-to-Equity: 0.34 (100% above median its 10-year median of 0.17)
GF Value™: kr2.94 vs. price of kr0.32 (89.2% below fair value)
Industry Position: 126.7% above the Biotechnology median (#648 of 966)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score
Get the complete analysis for OSTO:NICA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
